Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Ghoreschi K, et al. Among authors: kishore n. J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7. J Immunol. 2011. PMID: 21383241 Free PMC article.
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, Zhan Y, Bollinger CS, Bansal PN, Wellen JW, Wilkie DP, Bailey SA, Symanowicz PT, Hegen M, Head RD, Kishore N, Mbalaviele G, Meyer DM. LaBranche TP, et al. Among authors: kishore n. Arthritis Rheum. 2012 Nov;64(11):3531-42. doi: 10.1002/art.34649. Arthritis Rheum. 2012. PMID: 22899318 Free article.
Therapeutic targeting of Janus kinases.
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Pesu M, et al. Among authors: kishore n. Immunol Rev. 2008 Jun;223:132-42. doi: 10.1111/j.1600-065X.2008.00644.x. Immunol Rev. 2008. PMID: 18613833 Free PMC article. Review.
Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.
Sommers CD, Thompson JM, Guzova JA, Bonar SL, Rader RK, Mathialagan S, Venkatraman N, Holway VW, Kahn LE, Hu G, Garner DS, Huang HC, Chiang PC, Schindler JF, Hu Y, Meyer DM, Kishore NN. Sommers CD, et al. Among authors: kishore nn. J Pharmacol Exp Ther. 2009 Aug;330(2):377-88. doi: 10.1124/jpet.108.147538. Epub 2009 May 28. J Pharmacol Exp Ther. 2009. PMID: 19478133
Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides.
Baima ET, Guzova JA, Mathialagan S, Nagiec EE, Hardy MM, Song LR, Bonar SL, Weinberg RA, Selness SR, Woodard SS, Chrencik J, Hood WF, Schindler JF, Kishore N, Mbalaviele G. Baima ET, et al. Among authors: kishore n. J Biol Chem. 2010 Apr 30;285(18):13498-506. doi: 10.1074/jbc.M109.099895. Epub 2010 Feb 18. J Biol Chem. 2010. PMID: 20167598 Free PMC article.
250 results